Skip to main content

Table 1 Baseline demographic characteristics of the randomised patient population [18].

From: The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)

Variable Aripiprazole (N = 284) All SOC (N = 271) Total (N = 555)
Age, years
Mean 38.1 38.8 38.5
Median 36.5 37.0 37.0
SE 10.8 11.1 10.9
Gender, n (%)
Male 169 (59.5) 163 (60.1) 332 (59.8)
Female 115 (40.5) 108 (39.9) 223 (40.2)
Race, n (%)
White 274 (96.5) 262 (96.7) 536 (96.6)
Black 3 (1.1) 1 (0.4) 4 (0.7)
Asian 3 (1.1) 6 (2.2) 9 (1.6)
Other 4 (1.4) 2 (0.7) 6 (1.1)
Weight, kg
Mean 80.4 81.0 80.7
Median 79.0 79.0 79.0
SE 17.5 17.0 17.2
Missing   2 2
Schizophrenia type, n (%)
Disorganised 24 (8.5) 32 (11.8) 56 (10.1)
Catatonic 3 (1.1) 4 (1.5) 7 (13)
Paranoid 189 (66.5) 172 (63.5) 361 (65.0)
Residual 31 (10.9) 36 (13.3) 67 (12.1)
Undifferentiated 37 (13.0) 27 (10.0) 64 (11.5)
Age at time of first hospitalisation, years
Mean 28.3 28.7 28.5
Median 27.0 27.0 27.0
SE 8.5 8.7 8.6
Missing 35 26 61
Previous medication, N (%)
Any Antipsychotic Medication* 273 (96.1) 267 (98.5) 540 (97.3)
Olanzapine 75 (26.4) 85 (31.4) 160 (28.8)
Quetiapine 15 (5.3) 17 (6.3) 32 (5.8)
Risperidone 66 (23.2) 69 (25.5) 135 (24.3)
  1. * The remaining patients not accounted for by olanzapine, quetiapine and risperidone received a range of antipsychotic medication including amisulpride, benperidol, bromperidol, chlorpromazine, chlorprothixene, clozapine, cyamemazine, flupenthixol, fluphenazine, haloperidol, loxapine, melperone, methotrimeprazine, perazine, periciazine, perphenazine, pipamperone, pipothiazine, sertindole, sulpiride, thioridazine, trifluoperazine, ziprasidone, zotepine, zuclopenthixol